Ganetespib: Additional Phase IIb data

Additional interim data from 252 patients with stage IIIB/IV NSCLC adenocarcinoma in the open-label Phase IIb portion of the international Phase IIb/III GALAXY-1 trial showed that ganetespib plus docetaxel as second-line treatment led to a median OS, a secondary endpoint, of 9.8 vs. 7.4 months in patients receiving docetaxel alone

Read the full 502 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE